GW Pharmaceuticals PLC (GWPH) Rating Reiterated by Cowen and Company
GW Pharmaceuticals PLC (NASDAQ:GWPH)‘s stock had its “outperform” rating reaffirmed by equities researchers at Cowen and Company in a research report issued on Monday. They presently have a $165.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s price target suggests a potential upside of 59.07% from the stock’s previous close.
GWPH has been the subject of a number of other research reports. BidaskClub upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 target price on the stock in a research note on Monday, July 17th. Maxim Group set a $135.00 target price on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, June 8th. Leerink Swann reissued an “outperform” rating and set a $160.00 target price (down from $162.00) on shares of GW Pharmaceuticals PLC in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $149.83.
GW Pharmaceuticals PLC (GWPH) opened at 103.73 on Monday. The firm’s market cap is $2.63 billion. GW Pharmaceuticals PLC has a 52-week low of $92.65 and a 52-week high of $137.88. The stock has a 50 day moving average price of $105.35 and a 200 day moving average price of $108.25.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.34). The company had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same period last year, the firm posted ($0.05) earnings per share. Equities analysts predict that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/04/gw-pharmaceuticals-plc-gwph-rating-reiterated-by-cowen-and-company.html.
Several hedge funds and other institutional investors have recently bought and sold shares of GWPH. Janus Henderson Group PLC purchased a new stake in shares of GW Pharmaceuticals PLC during the 2nd quarter valued at approximately $70,128,000. Redmile Group LLC grew its stake in GW Pharmaceuticals PLC by 33.8% in the 2nd quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after buying an additional 112,392 shares in the last quarter. Renaissance Technologies LLC purchased a new position in GW Pharmaceuticals PLC in the 1st quarter valued at approximately $10,909,000. Nomura Holdings Inc. purchased a new position in GW Pharmaceuticals PLC in the 1st quarter valued at approximately $9,389,000. Finally, Employees Retirement System of Texas purchased a new position in GW Pharmaceuticals PLC in the 2nd quarter valued at approximately $5,313,000. 75.06% of the stock is currently owned by institutional investors.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.